1
HAYASHI Keishi, WATANABE Tsuneo, TOYAMA Koji, KAMON Junji, MINAMI Masataka, UNI Miyuki, NASU Mariko: [fr] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES ET INHIBITEURS DE JAK, [en] TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS. HAYASHI Keishi, WATANABE Tsuneo, TOYAMA Koji, KAMON Junji, MINAMI Masataka, UNI Miyuki, NASU Mariko, NISSAN CHEMICAL, SENMYO Kenji, February 21, 2013: WO/2013/024895 (16 worldwide citation)

[en] Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a, L2a, L3a and na are as defined in the description.


2

3
Matsumoto Takahiro, Kamo Izumi, Nomura Izumi: Tricyclic heterocyclic compound and use thereof. Takeda Pharmaceutical Company, Matsumoto Takahiro, Kamo Izumi, Nomura Izumi, TAKASHIMA Hajime, January 17, 2008: WO/2008/007661 (14 worldwide citation)

Disclosed is a tricyclic heterocyclic compound having a serotonin 5-HT2C receptor activating effect and the like. Specifically disclosed is a serotonin 5-HT2C receptor activator containing a compound represented by the formula (I) below, a salt thereof or a prodrug thereof. (I) (In the formula, the ...


4
Yoshida Akira, Oda Kozo, Kasai Takashi, Koga Teiichiro, Hasegawa Kazuo: Tricyclic heterocyclic compound.. Sankyo, February 1, 1995: EP0636619-A1 (2 worldwide citation)

[Constitution] A tricyclic heterocyclic compound represented by general formula (I) wherein R and R represent each hydrogen, lower alkyl, lower alkoxy, halogen or halogenated lower alkyl; R represents hydrogen or lower alkyl; R represents substituted phenyl or naphthyl; R represents hydrogen or lowe ...


5
Amino-alkanoyl dibenzoxaza- and dibenzothiaza-heterocyclic compounds. Squibb & Sons, June 13, 1970: GB1192016-A (2 worldwide citation)

1,192,016. Dibenzoxaza- and dibenzothiazaheterocyclic compounds. E. R. SQUIBB & SONS Inc. 17 April, 1967 [29 April, 1966], No. 17442/67. Heading C2C. Novel compounds of the Formula I wherein R is H, C 1-7 alkyl, monocyclic aryl; R1 and R2, which may be the same or different, are H, C 1-7 alkyl, or a ...


6
Keishi Hayashi, Tsuneo Watanabe, Koji Toyama, Junji Kamon, Masataka Minami, Miyuki Uni, Mariko Nasu: Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors. Nissan Chemical, Oblon McClelland Maier & Neustadt L, December 22, 2015: US09216999 (1 worldwide citation)

Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (Ia): wherein the rings Aa and Ba, Xa, Ya, R1a, R2a, R3a, L1a L2a, L3a and na are as defined in the description.


7
Kawamoto Isao, Sugano Osamu, Kobayashi Shino, Shimoji Yasuo, Oya Satoru: Antimicrobial agent containing tricyclic hetrocyclic compound. Sankyo, February 22, 2000: JP2000-053681 (1 worldwide citation)

PROBLEM TO BE SOLVED: To obtain an antimicrobial agent having excellent stability to dehydropeptidase I, having a high recovery ratio in urine, low toxicity, capable of exhibiting excellent antimicrobial activity, useful for treating and preventing bacteriosis, etc., by including a specific tricycli ...


8
Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Kamo Izumi, Shirai Junya: Tricyclic heterocyclic compound, method for producing the same and its use. Takeda Chem, May 28, 2002: JP2002-155084 (1 worldwide citation)

PROBLEM TO BE SOLVED: To obtain a cyclic heterocyclic compound having excellent tachykinin receptor antagonism.SOLUTION: This compound is represented by general formula (I) [R1 is H, an alkyl, an aryl, an acyl, an alkoxycarbonyl, carbamoyl, a mono- or dialkylcarbamoyl or an alkylsulfonyl which may b ...


9
Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Kamo Izumi, Shirai Junya: Tricyclic heterocyclic compound, producing method of the same, and its use. Takeda Chem, December 4, 2002: JP2002-348289 (1 worldwide citation)

PROBLEM TO BE SOLVED: To obtain a compound with an excellent tachykinin receptor antagonism, especially a substance P receptor antagonism. SOLUTION: This comound, its salt, or its prodrug is expressed by formula 1 (wherein, a A-ring is a substituted pyridine ring; R2 is a hydrogen atom, a halogen at ...


10
Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Kamo Izumi, Shirai Junya: Tricyclic heterocyclic compound, process for producing the same, and use thereof. Takeda Chemical Industries, Ikeura Yoshinori, Hashimoto Tadatoshi, Tarui Naoki, Kamo Izumi, Shirai Junya, TAKASHIMA Hajime, March 21, 2002: WO/2002/022574 (1 worldwide citation)

A compound represented by the formula, a salt thereof, or a prodrug thereof: (I) wherein R?1¿ represents hydrogen, optionally substituted alkyl, aryl, acyl, alkoxycarbonyl, carbamoyl, mono- or dialkylcarbamoyl, or alkylsulfonyl; R?2¿ represents hydrogen, halogeno, or optionally halogenated alkyl; R? ...